Arotinolol hydrochloride's dual-mechanism clinical niche — the alpha and beta-adrenergic receptor blocking agent used primarily in the treatment of hypertension, essential tremor, and hyperthyroidism-related symptoms, distinguished from single-mechanism beta-blockers by its combined alpha-1 and beta-adrenergic blocking activity — represents a clinically differentiated but...